New avenue for developing disease-modifying therapies of Alzheimer's disease: Reassessment of Amyloid-β as the primary target
Since 2000, we have held annual international symposia aming at contributing to the development in neuroscience research by further international collaborations.
At the 15th MNRC International Symposium, Dr. Masaki Nishimura, Associate
Professor of Neurology Unit, has invited leading active international and
domestic researchers who gave presentations focused on “New avenue for developing
disease-modifying therapies of Alzheimer's disease”.
Opening Remarks:
President Tadao Bamba
(President and Dean, Shiga University of Medical Science)
Welcome Remarks:
Ikuo Tooyama
(Director of MNRC, Shiga University of Medical Science)
Aims and scope:
Masaki Nishimura
(MNRC, Shiga University of Medical Science)
"A Neuroprotection Framework in Cerebral Ischemia Based on a 'Stroke in a Dish' Model"
Paul Fraser (University of Toronto)
"Possible Pathogenesis of Sporadic Alzheimer's Disease"
Toshiharu Suzuki (Hokkaido University)
"Aβ Reduction by Targeting the Penultimate Precursor"
Lei Liu and Masaki Nishimura (SUMS)
"Toward a Relationship Between Aβ Oligomer and Amyloid Hypothesis"
Hiroshi Mori (Osaka City University)
"Aβ Oligomer Immunotherapy as a Potential Disease-modifying Therapy for
Alzheimer's Disease"
Etsuro Matsubara (Hirosaki University)
Closing remarks:
Vice President Takanori Hattori (Vice President and Dean, Shiga University
of Medical Science)
At the reception party
from left
Associate Professor, Masaki Nishimura, MNRC
Associate Professor, Etsuro Matsubara, Hirosaki University
Professor Toshiharu Suzuki, Hokkaido University
Professor Paul Fraser, University of Toronto
Professor Hiroshi Mori, Osaka City University
Professor Ikuo Tooyama, Director of MNRC